These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20373668)

  • 1. Psychiatric pharmacogenomic testing in clinical practice.
    Mrazek DA
    Dialogues Clin Neurosci; 2010; 12(1):69-76. PubMed ID: 20373668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
    Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
    Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
    Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG
    Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.
    de Leon J; Armstrong SC; Cozza KL
    Psychosomatics; 2006; 47(1):75-85. PubMed ID: 16384813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review.
    Wehry AM; Ramsey L; Dulemba SE; Mossman SA; Strawn JR
    Curr Probl Pediatr Adolesc Health Care; 2018 Feb; 48(2):40-49. PubMed ID: 29325731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics in psychiatry: implications for practice.
    Moore TR; Hill AM; Panguluri SK
    Recent Pat Biotechnol; 2014; 8(2):152-9. PubMed ID: 25185985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.
    Peñas-Lledó EM; Llerena A
    Br J Clin Pharmacol; 2014 Apr; 77(4):673-83. PubMed ID: 24033670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial.
    Jürgens G; Andersen SE; Rasmussen HB; Werge T; Jensen HD; Kaas-Hansen BS; Nordentoft M
    JAMA Netw Open; 2020 Dec; 3(12):e2027909. PubMed ID: 33284338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism.
    Vandel P; Talon JM; Haffen E; Sechter D
    Curr Pharm Des; 2007; 13(2):241-50. PubMed ID: 17269931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacogenetics/pharmacogenomics in psychiatry].
    Ueda M; Ishiguro S; Watanabe T; Saeki Y; Shimoda K
    Nihon Rinsho; 2010 Jan; 68(1):155-62. PubMed ID: 20077810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
    Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
    Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility and Economic Impact of CYP2D6 Genotyping.
    Reynolds KK; McNally BA; Linder MW
    Clin Lab Med; 2016 Sep; 36(3):525-42. PubMed ID: 27514466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics in Psychiatric Practice.
    El-Mallakh RS; Roberts RJ; El-Mallakh PL; Findlay LJ; Reynolds KK
    Clin Lab Med; 2016 Sep; 36(3):507-23. PubMed ID: 27514465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations.
    Rogers HL; Bhattaram A; Zineh I; Gobburu J; Mathis M; Laughren TP; Pacanowski M
    J Clin Psychiatry; 2012 Sep; 73(9):1187-90. PubMed ID: 23059146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of Cytochrome P450 Enzymes in American Indian and Caucasian Children Admitted to a Psychiatric Hospital.
    McGrane IR; Loveland JG
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):395-9. PubMed ID: 26871369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?
    Herbild L; Andersen SE; Werge T; Rasmussen HB; Jürgens G
    Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):266-72. PubMed ID: 23731498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
    Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
    Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital.
    de Leon J; Barnhill J; Rogers T; Boyle J; Chou WH; Wedlund PJ
    Am J Psychiatry; 1998 Sep; 155(9):1278-80. PubMed ID: 9734555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.